>> HOMEPAGE

Heart Failure

The clinical and hemodynamic effects of coenzyme Q10 in congestive cardiomyopathy.

Sacher HL; Sacher ML; Landau SW; Kersten R; Dooley F; Sacher A; Sacher M; Dietrick K; Ichkhan K

Am J Ther 1997 Feb-Mar;4(2-3):66-72

Despite major advances in treatment congestive heart failure (CHF) is still one of the major causes of morbidity and mortality. Coenzyme Q(10) is a naturally occurring substance that has antioxidant and membrane stabilizing properties. Administration of coenzyme Q(10) in conjunction with standard medical therapy has been reported to augment myocardial kinetics, increase cardiac output, elevate the ischemic threshold, and enhance functional capacity in patients with congestive heart failure. The aim of this study was to investigate some of these claims. Seventeen patients (mean New York Heart Association functional class 3.0 +/- 0.4) were enrolled in an open-label study. After 4 months of coenzyme Q ( 10 ) therapy, functional class improved 20% (3.0 +/- 0.4 to 2.4 +/- 0.6, p < 0.001) and there was a 27% improvement in mean CHF score (2.8 +/- 0.4 to 2.2 +/- 0.4, p < 0.001). Percent change in the resting variables included the following: left ventricular ejection fraction (LVEF), +34.8%; cardiac output, +15.7%; stroke volume index, +18.9%; end-diastolic volume area, -8.4%; systolic blood pressure (SBP), -4. 4%; and E (max), (SBP / end-systolic volume index [ESVI]) +11.7%. MVo ( 2 ) decreased by 5.3% (31.9 +/- 2.6 to 30.2 +/- 2.4, p = NS). Therapy with coenzyme Q(10) was associated with a mean 25.4% increase in exercise duration and a 14.3% increase in workload. Percent changes after therapy include the following: exercise LVEF, +24.6%; cardiac output, +19.1%; stroke volume index, +13.2%; heart rate, +6.5%; SBP, -4.3%; SBP / ESVI, +18.6%; end-diastolic volume (EDV) area, -6.0%; MVo (2), -7.0%; and ventricular compliance (%Delta SV / EDV) improved >100%. In summary, coenzyme Q(10) therapy is associated with significant functional, clinical, and hemodynamic improvements within the context of an extremely favorable benefit-to-risk ratio. Coenzyme Q(10) enhances cardiac output by exerting a positive inotropic effect upon the myocardium as well as mild vasodilatation.

Sitemap

Was ist neu:

Unsere Verantwortung für die Schaffung einer Welt der Gesundheit, des Friedens und der sozialen Gerechtigkeit

Neue Studie würdigt die Rolle von Vitamin C bei der Reduktion von herzkreislaufbedingter Sterblichkeit

Mehr Kranke bitte! – Abrechnungsbetrügerei mit System

Wenn Arzneimittel verpflichtend werden: Pharma stiftet Gerichte dazu an, Opiod-Abhängige einem Drogenprogramm zu unterwerfen – mit Kosten von $1000 je Injektion

Depressionen infolge Vitamin B-Mangel – ein neuer wissenschaftlicher Review steigert die Beweislast

Neue Metaanalyse stellt wiederum den Nutzen von Magnesium bei Bluthochdruck unter Beweis

Die Cholesterin-Herzinfarkt-Hypothese ist “tot”, bestätigt die britische Königliche Pharmazeutische Gesellschaft

Erfrischung pur – Über die Bedeutung von Trinkwasser im menschlichen Körper

» Natürliche Gesundheit

» "Geschäft m. d. Krankheit"

» Internationale Kampagne

» Dr. Raths Offene Briefe

» Studien weltweit

» Studien auf Deutsch

» Helfen Sie mit!

» Codex Alimentarius

» Dossiers

» Sitemap

Dr. Rath Health Foundation auf Facebook Dr. Rath Health Foundation auf YouTube Dr. Rath Health Foundation auf Twitter RSS
 © 2017 Dr. Rath Health Foundation | Kontakt | Impressum | RSS Feed